Clinical trials examining medication discontinuation have consistently demonstrated significant weight regain after stopping GLP-1 therapy
However, at this stage, we do not yet have sufficient high-quality human data to fully understand the safety, efficacy, and long-term effects of BPC-157
Glucagon-like peptide-1 (GLP-1)-based therapies, such as semaglutide and tirzepatide, have transformed obesity management, producing weight loss that narrows the gap with metabolic surgery at the same time as reducing the risk of obesity-related complications [2]
This is where working with specialists becomes invaluable, as they can design integrated protocols that address your complete health picture
When incorporating impacts from the various indications of incretin-based therapies, care should be taken to avoid double-counting
Plant Cell 26(5):19131924